This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks to Watch: ICE, NYSE, Bed Bath, RIM

NEW YORK -- NYSE Euronext (NYX), the operator of the New York Stock Exchange, is in talks to sell itself to rival IntercontinentalExchange (ICE - Get Report), according to reports.

People close to the discussions told The Wall Street Journal an announcement could come as early as Thursday.

Under a deal, ICE would value NYSE at $33 a share, a 37% premium to its closing price on Wednesday, according to a report from CNBC.

NYSE closed Wednesday at $24.05 and soared more than 20% in after-hours trading.


Bed Bath & Beyond (BBBY - Get Report) on Wednesday issued forecasts for the fourth quarter and fiscal year that were below analysts' views.

The retailer said it expects fourth-quarter earnings of $1.60 to $1.67 a share, and fiscal-year earnings of $4.48 to $4.54 a share.

Analysts are calling for fourth-quarter earnings of $1.75 a share, and 2012 earnings of $4.62 a share.

Bed Bath & Beyond's board also authorized a new $2.5 billion stock buyback program.

5 Retail Sector Bargains to Buy Before 2013


Jabil Circuit (JBL - Get Report) posted fiscal first-quarter earnings on Wednesday that topped Wall Street estimates.

Adjusted earnings for the first quarter were 61 cents a share; analysts forecast profit of 56 cents a share.

Jabil said sales in the quarter rose to $4.64 billion from $4.33 billion a year earlier. Analysts were expecting sales of $4.41 billion.

Stephen Gillett Leaves Sinking-Ship Best Buy for Symantec


Research In Motion (RIMM), the BlackBerry maker, is expected by analysts on Thursday to post a fiscal third-quarter loss of 35 cents a share.

RIM, which has steadily been losing market share in the U.S., is banking on reversing its fortunes with BlackBerry 10, the new operating system that will be unveiled at the end of next month.


An experimental therapy from Amicus Therapeutics (FOLD) and GlaxoSmithKline (GSK) failed to improve kidney response in Fabry disease patients compared to placebo in a late-stage study, the companies disclosed late Wednesday.

Amicus shares closed Wednesday at $5.77 but fell 55% to $2.60 in after-hours trading.

Amicus Fabry Drug Fails Pivotal Trial


Analysts expect ConAgra Foods (CAG) on Thursday to report fiscal second-quarter earnings of 55 cents a share on revenue of $3.69 billion.


Discover Financial Services (DFS) is expected by Wall Street to post fourth-quarter earnings Thursday of $1.11 a share.


-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NYX $0.00 0.00%
BBBY $60.92 -1.90%
JBL $18.88 -2.40%
ICE $225.02 -1.50%
AAPL $110.83 -1.70%

Markets

Chart of I:DJI
DOW 16,165.65 -362.38 -2.19%
S&P 500 1,932.06 -40.12 -2.03%
NASDAQ 4,696.8210 -79.6870 -1.67%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs